A Latin American perspective on the new ACC/AHA clinical guidelines for managing atherosclerotic cardiovascular disease

Current Atherosclerosis Reports

Volumn 16, Issue 4, 2014, Pages

  Cuevas, Ada ^a   Arteaga, Antonio ^b   Rigotti, Attilio ^b  

^a CLÍNICA LAS CONDES   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cardiovascular disease; Cardiovascular risk; Cholesterol treatment; Clinical guidelines; Latin America; Lifestyle; Risk assessment

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PREVENTION STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOUTH AND CENTRAL AMERICA; TREATMENT PLANNING; ANIMAL; CEREBROVASCULAR ACCIDENT; LIFESTYLE; REVIEW; SOUTH AMERICA;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SOUTH AMERICA; STROKE;

EID: 84893162210     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0400-x     Document Type: Article

References (48)

1. World Health Organization. Word health statistics. http://www.who.int/ gho/publications/world-health-statistics (2014).
2. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, SilvaAyçaguer LC, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008;121(1):58-65.
3. Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One. 2013;8(1): e54056.
4. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007;115(9): 1067-74. (Pubitemid 46673168)
5. Vinueza R, Boissonnet CP, Acevedo M, Uriza F, Benitez FJ, Silva H, et al. Dyslipidemia in seven Latin American cities: CARMELA study. Prev Med. 2010;50(3):106-11.
6. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42(8):1298-307. (Pubitemid 32744254)
7. EPI. Resultados Encuesta Nacional de Salud 2009 - 2010. Available from: http://epi.minsal.cl/estudios-y-encuestaspoblacionales/encuestas-poblacionales/ encuesta-nacional-desalud/resultados-ens (2012).
8. Tejero ME. Cardiovascular disease in Latin American women. Nutr Metab Cardiovasc Dis. 2010;20(6):405-11.
9. Margozzini P, Rigotti A, Ferreccio C, Quezada N, Garrido M, Valdés G. Hypertension and the cardiometabolic syndrome in Chile: a review of concepts and consequences for the developing world. Ther Adv Cardiovasc Dis. 2007;1(1):83-90.
10. Valenzuela AA, Maíz A, Margozzini P, Ferreccio C, Rigotti A, Olea R, et al. Prevalence of metabolic syndrome among Chilean adults. Rev Med Chil. 2010;138(6):707-14.
11. Cuevas A, Alvarez V, Carrasco F. Epidemic of metabolic syndrome in Latin America. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):134-8.
12. Lerman-Garber I, Villa AR, Caballero E. Diabetes and cardiovascular disease: is there a true Hispanic paradox? Rev Investig Clin. 2004;56(3):282-96. (Pubitemid 39232125)
13. Cortes-Bergoderi M, Goel K, Murad MH, Allison T, Somers VK, Erwin PJ, et al. Cardiovascular mortality in Hispanics compared to non-Hispanic whites: a systematic review and meta-analysis of the Hispanic paradox. Eur J Intern Med. 2013;24(8):791-9.
14. LaRosa JC, Gotto Jr AM. Past, present, and future standards for management of dyslipidemia. Am J Med. 2004;116(Suppl 6A):3S-8S.
15. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005;96(4A):53E-9E. (Pubitemid 41140371)
16. Goff Jr DC, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013. 11.005.
17. Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013. 11.003.
18. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1016/j.jacc.2013.11.002.
19. Valluri S, Gaziano TA. Progress in national and regional guidelines development and deployment for the clinical prevention and control of CVD and diabetes in Africa. Prog Cardiovasc Dis. 2013;56(3): 336-43.
20. Santos RD, Lorenzatti AJ, Barros CF, Escobar E. Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. J Clin Lipidol. 2011;5(3):124-32. doi:10.1016/j.jacl.2011.02.006.
21. International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. International Atherosclerosis Society. 2013. http://www.athero. org/download/IASPPGuidelines-FullReport-2.pdf.
22. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-5.
23. Cortes-Bergoderi M, Thomas RJ, Albuquerque FN, Batsis JA, Burdiat G, Perez-Terzic C, et al. Validity of cardiovascular risk prediction models in Latin America and among Hispanics in the United States of America: a systematic review. Rev Panam Salud Publica. 2012;32(2):131-9.
24. Olivos C, Valenzuela A, Arteaga A, Margozzini P, Olea R, Maiz A, et al. Cardiovascular risk, cholesterol goal attainment, and lipidlowering eligibility in Chile. Findings from the first national health survey. Atheroscler Suppl. 2007;8(1):121-2.
25. Icaza G, Núñez L, Marrugat J, Mujica V, Escobar MC, Jiménez AL, et al. Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations. Rev Med Chil. 2009;137(10):1273-82.
26. Rubinstein AL, Irazola VE, Poggio R, Bazzano L, Calandrelli M, Lanas Zanetti FT, et al. Detection and follow-up of cardiovascular disease and risk factors in the southern cone of Latin America: the CESCAS I study. BMJ Open. 2011;1(1):e000126.
27. Aquino EM, Barreto SM, Bensenor IM, Carvalho MS, Chor D, Duncan BB, et al. Brazilian Longitudinal study of adult health (ELSA-Brasil): objectives and design. Am J Epidemiol. 2012;175(4):315-24.
28. de Lorgeril M. Mediterranean diet and cardiovascular disease: historical perspective and latest evidence. Curr Atheroscler Rep. 2013. doi: 10.1007/s11883-013-0370-4.
29. Bermudez O, Tucker K. Trends in dietary patterns of Latin American populations. Cad Saude Publica. 2003;19(Supp 1):S87-99.
30. Cuevas A, Alvarez V, Olivos C. The emerging obesity problem in Latin America. Expert Rev Cardiovasc Ther. 2009;7(3):281-8.
31. Uauy R, Albala C, Kain J. Obesity trends in Latin America: transition from under to over nutrition. J Nutr. 2001;131(3):S893-9.
32. Aschner P, Ruiz A, Balkau B, Massien C, Haffner SM. Association of abdominal adiposity with diabetes and cardiovascular disease in Latin America. J Clin Hypertens (Greenwich). 2009;11(12):769-74.
33. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-62. (Pubitemid 41338752)
34. Rocha AP, Carvalho LC, Sousa MA, Madeira SV, Sousa POJ, Tano T, et al. Endothelium dependent vasodilator effect of Euterpe oleracea Mart. Acaí extracts in mesenteric vascular bed of the rat. Vasc Pharmacol. 2007;46:97-104. (Pubitemid 44937680)
35. Ruiz A, Hermosín-Gutiérrez I, Mardones C, Vergara C, Herlitz E, Vega M, et al. Polyphenols and antioxidant activity of calafate (Berberismicrophylla) fruits and other native berries from southern Chile. J Agric Food Chem. 2010;58(10):6081-9.
36. Olavarria S, Zacarias I. Barriers and facilitators to increase consumption of fruits and vegetables in six countries in Latin America. Arch Latinoam Nutr. 2011;61(2):154-62.
37. Garmendia ML, Corvalan C, Uauy R. Addressing malnutrition while avoiding obesity: minding the balance. Eur J Clin Nutr. 2013;67(5):513-7.
38. Champagne BM, Sebrié EM, Schargrodsky H, Pramparo P, Boissonet C, Wilson E. Tobacco smoking in seven Latin America cities. The CARMELA study. Tob Control. 2010;19(6):457-62.
39. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) guidelines for treatment of dyslipidemia in a non-Caucasian population: a Mexican nation-wide survey. Rev Investig Clin. 2005;57(1):28-37. (Pubitemid 40716198)
40. Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis. 2012;224(1):150-3.
41. Tonelli M, Wanner C. Lipidmanagement in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med. 2013. doi:10.7326/M13-2453.
42. Psaty BM, Weiss NS. ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2013. doi:10.1001/jama.2013.284203.
43. Ioannidis JP. More than a billion people taking statins?: potential implications of the new cardiovascular guidelines. JAMA. 2013. doi:10.1001/jama.2013.284657.
44. Tolonen H, Keil U, Ferrario M, Evans A. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA project. Int J Epidemiol. 2005;34:181-92. (Pubitemid 40347392)
45. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-43.
46. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in high-risk individuals in low-income andmiddle-income countries: health effects and costs. Lancet. 2007;370(9604):2054-62. (Pubitemid 50007974)
47. Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, et al. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff (Millwood). 2013;32(1):155-64.
48. Valdivieso V, Rigotti A. Health research in Latin America. Lancet. 2010;375(9709):120-1.